Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report describes complete hair regrowth in a patient with alopecia universalis and improved psoriasis after treatment with the oral Janus kinase inhibitor, tofacitinib.

This study observed that tofacitinib therapy over about 16 weeks had a positive effect in children with alopecia areata, reducing the SALT index significantly in some patients.

This article is a letter to the editor discussing potential therapeutic synergy between a wig-fixing device and tofacitinib for treating alopecia areata but reports no new clinical results.

This study found that in alopecia areata, treatment with the oral JAK-inhibitor tofacitinib decreased clonally expanded CD8⁺ T cells in the scalp, but many expanded clones did not completely disappear, potentially leading to relapse after stopping treatment.

In this study, retrospective analysis of patients with severe alopecia areata showed that oral JAK inhibitors, tofacitinib and baricitinib, reduced hair loss significantly, with comparable effectiveness; longer tofacitinib use was linked to greater improvement, while baricitinib achieved substantial outcomes quickly.

This study involving 126 patients found that tofacitinib has high effectiveness and an acceptable safety profile for treating alopecia areata, with a 33.8% complete response rate at 24 weeks and sex as an independent risk factor for outcomes.

This paper reviews the challenges of treating alopecia areata affecting eyelashes and discusses the risks associated with traditional therapies; it reports no new clinical results.

In this study, prolonged intravenous Fenoterol infusion was associated with intensive hair growth in most patients, although hormonal changes typically linked to such effects were not observed.

In this study, gelatin-coated transferosomes were developed to deliver tofacitinib specifically to hair follicles, resulting in 80% hair regrowth in alopecia areata patients with recalcitrant lesions after 12 weeks of treatment.

This study found that tofacitinib shows reasonable effectiveness for treating alopecia areata with mild adverse effects, although more large-scale randomized trials are needed to fully assess its safety and efficacy.

This study found that tofacitinib effectively promoted hair regrowth in Asian patients with severe alopecia areata, with 74.3% showing a clinical response.

Tacalcitol ointment effectively improves bilateral nevus comedonicus.

This review highlights the potential of TCM medicinal foods for managing post-COVID disorders and suggests they could provide a safe and efficient long-term therapy due to their milder nature.

This study observed that tributyltin pollution induces imposex, reduces reproductive success, and leads to population decline in Ocinebrina aciculata, highlighting its sensitivity compared to other prosobranch species.

This case report describes significant therapeutic effects from Tofacitinib Citrate Sustained-Release Tablets in a patient with Alopecia Areata, while highlighting the economic burden of long-term treatment.

This review examines the outcomes of treating Brazilian patients with alopecia universalis using tofacitinib and highlights the need for randomized controlled trials to determine optimal dosing and duration.

This letter discusses the emerging use of Janus kinase inhibitors, specifically oral tofacitinib, for treating alopecia areata in children, but reports no new clinical findings.

In this study, tofacitinib treatment led to significant hair regrowth in 60% of patients with moderate-to-severe alopecia areata, suggesting potential for JAK inhibitors in treating this condition.

This article discusses alopecia areata, highlighting its autoimmune nature and the lack of FDA-approved treatments, without providing new research findings.

In this multi-center, retrospective cohort study, researchers found that tofacitinib significantly reduced SALT scores and improved eyebrow and eyelash regrowth in patients with refractory alopecia areata after 12 weeks, with greater efficacy observed in severe cases and consistent results across pediatric and adult populations.

This study suggests that chronic treatment with TPA in mouse skin selectively expands a keratinocyte subpopulation hyperinducible for ODC, which may be a key target for neoplastic transformation.

This case series found that oral tofacitinib treatment in eight adolescents with alopecia universalis led to significant regrowth of hair, though relapse is likely after stopping therapy.

This article discusses the trichoscopic diagnosis of temporal triangular alopecia, but reports no new clinical results.

In this study, topical tofacitinib significantly promoted hair regrowth in mice, outpacing both minoxidil and controls over 21 days, with findings suggesting increased VEGF levels and decreased inflammation as possible mechanisms.

In this case series, dual-targeted therapy was observed to provide promising clinical responses in refractory inflammatory bowel disease, with 88.23% to 100% response rates across 9 months and an endoscopic response in 88.89% of evaluated patients, though some adverse events occurred.

This study describes the ongoing HABIT study in Taicang, China, which aims to identify risk factors and the relationship between cardiovascular and neurodegenerative diseases among 10,357 adults, by collecting and analyzing long-term data on health, lifestyle, and biological specimens. Results are not yet available.

This review concluded that oral tofacitinib and adalimumab are promising treatments for cicatricial alopecia, showing effectiveness in improving signs and symptoms but requiring regular monitoring for adverse effects. The authors emphasize the need for further extensive studies to solidify these findings.

This study evaluated the efficacy and safety of tofacitinib for treating severe alopecia areata in five patients, finding that three responded favorably with mild side effects, supporting its potential use based on existing research.

This study suggests that oral tofacitinib may be an effective treatment for beard regrowth in men with alopecia areata of the beard, with a strong correlation observed between beard and scalp hair regrowth.

This retrospective cohort study reported that oral tofacitinib was effective in treating alopecia areata, with 83.2% of patients showing improvement and 16.0% achieving complete remission. Earlier intervention and previous hair regrowth were linked to better outcomes, and no severe adverse events were observed.